<DOC>
	<DOC>NCT02074358</DOC>
	<brief_summary>The purpose of this study is to assess the effect of two 4-Factor PCC formulations on Apixaban pharmacodynamics in healthy adult subjects.</brief_summary>
	<brief_title>A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Healthy subjects Body Mass Index (BMI) of 18 to 30 kg/m2 Ages 18 to 45 years, including Women of childbearing potential (WOCBP) on acceptable contraception and with negative pregnancy test and not breastfeeding History or evidence of coagulopathy History or evidence of thrombosis such as deep vein thrombosis or other thromboembolic disease or having a first degree relative under 50 years of age with a history of thromboembolic disease Any significant acute or chronic medical illness or relevant trauma Any major surgery within 4 weeks of dosing (prior to dosing) or planned within 2 weeks after completion of the study History of heavy menstrual bleeding that has produced anemia within the past 1 year Current symptomatic or recent gastrointestinal disease or surgery that could impact the absorption of study drug History of smoking within 1 month prior to dosing Recent history (within 6 months of dosing) of pregnancy Use of hormonal contraceptives Exposure to any investigational drug or placebo within 4 weeks of study drug administration Use of any agent, including but not limited to Aspirin, Nonsteroidal antiinflammatory drugs (NSAIDs), Anticoagulants, Fish oil capsules, Gingko, etc, that are known to increase the potential for bleeding, within 2 weeks prior to dosing History of any severe drug allergy including allergy to Heparin or history of Heparininduced thrombocytopenia, hypersensitivity to PCCs or Factor Xa inhibitors, or history of allergy to human blood plasma derived products; history of any adverse drug reaction to Anticoagulants or Antiplatelet agents that resulted in excessive bleeding requiring medical intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>